公司近期动态 - Senti Bio首席执行官Timothy Lu博士将于2026年1月13日太平洋时间上午8:00在旧金山举行的Biotech Showcase 2026会议上参加题为“Engineering the Future: Advances in Cell and Gene Therapies”的小组讨论 [1][2] - 小组讨论地点为Workshop 1 (Yosemite A) [2] - 公司鼓励投资者通过其官网、X和LinkedIn等渠道获取公司披露、投资者演示文稿、SEC文件、新闻稿等可能被视为重要的信息 [5] 公司业务与平台介绍 - Senti Bio是一家临床阶段生物技术公司，致力于利用其专有的基因回路平台开发新一代细胞和基因疗法 [1] - 公司利用合成生物学平台设计基因回路，旨在开发具有更高精度和可控性的新药 [4] - 这些基因回路被设计用于精确杀死癌细胞、保护健康细胞、提高对靶组织的特异性，和/或在给药后仍可控制 [4] - 公司全资拥有的研发管线包括针对具有挑战性的血液瘤和实体瘤适应症的、经基因回路工程改造的细胞疗法 [4] - 临床前研究表明，Senti的基因回路在NK细胞和T细胞中均能发挥作用 [4] - 公司还在临床前证明了基因回路在肿瘤学以外的其他治疗模式和疾病中的潜在广度，并通过合作伙伴关系持续推进这些能力 [4] 行业会议背景 - Biotech Showcase是一个致力于为私人和公共生物技术及生命科学公司提供向投资者和制药高管展示及会面机会的投资与交流会议 [3] - 该会议已举办至第17年，设有多个公司展示轨道、全体会议、研讨会、交流活动以及一对一会议安排机会 [3] - 会议由Demy-Colton和EBD Group组织举办，这两家机构在举办支持生物技术及更广泛生命科学行业的高质量项目方面拥有悠久历史 [3]

CHARLOTTE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Magnera (NYSE: MAGN) expects to release its first quarter results prior to trading on the New York Stock Exchange on Thursday, February 5, 2026. The earnings release, along with an investor presentation, will be available shortly thereafter on Magnera’s website at Investor Relations – Magnera. In conjunction with its release, Magnera will hold a conference call to discuss the first quarter financial results at 10:00 a.m. (ET) on Thursday, February 5, 2026. ...

MONTREAL, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cerro de Pasco Resources Inc. (TSXV CDPR) (OTCQB GPPRF) (FRA N8HP) (the Company or CDPR) is pleased to provide an operational review and corporate update highlighting key workstreams completed and consolidated at the Quiulacocha Tailings Project, as the Company transitions toward the next stage of project execution. This update builds on the technical and permitting progress outlined in the Company’s December 10, 2025 news release and reflects the completion and i ...

公司核心进展 - PDS Biotechnology公司已向美国食品药品监督管理局提交了其III期VERSATILE-003临床试验方案的修正案 [1] - 该修正案将无进展生存期更改为一个可以更早评估的主要终点，并具有显著的统计学效力，这可能为PDS0101的加速批准提供基础 [1] - 中位总生存期仍然是完全批准的主要终点，这与FDA最初的建议一致 [1] 监管沟通与支持依据 - 此次提交是基于2025年12月与FDA举行的一次建设性的C类会议，会议讨论了PDS0101针对HPV16阳性复发性和/或转移性头颈癌的加速批准路径 [2] - 该修正案得到了公司VERSATILE-002试验积极最终结果的支持，该试验显示了有希望的中位总生存期和持久的无进展生存期 [2] 管理层观点与战略意义 - 公司管理层认为，将无进展生存期纳入主要终点为缩短VERSATILE-003试验的持续时间提供了重要机会 [3] - 修正案保留了中位总生存期和安全性作为获得FDA完全批准的要求 [3] - 基于2025年12月与监管机构的对话，公司相信已获得一条可能加速其监管提交的路径 [3] 公司业务与研发管线 - PDS Biotechnology是一家后期免疫治疗公司，专注于改变免疫系统靶向和杀死癌症的方式 [4] - 公司已启动一项关键临床试验，以推进其针对晚期HPV16阳性头颈部鳞状细胞癌的主要研发项目 [4] - 其主要研究性靶向免疫疗法PDS0101正在与标准护理免疫检查点抑制剂联合开发，同时也作为三联疗法的一部分进行开发，该三联疗法还包括PDS01ADC和一种标准护理免疫检查点抑制剂 [4]

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options THE WOODLANDS, TX, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced new subgroup clinical data from its PoC study presented at the 2026 ASCO Gastrointestinal (G ...

- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to evaluate an investigational therapy in intermediate-risk NMIBC IRVINE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced an expedited timeline for the topline data readout now expected in the first half of 2026 for the Phase 3 PIVOT-006 clinical trial comparing adjuvant ...

Oversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo CapitalInitial financing tranche of over $6 million, which we expect will provide cash runway into the third quarter of 2026 enabling funding through potential NDA acceptance decision by the FDA, with two additional financing tranches totaling over $22 million contingent on NDA acceptance and NDA approval by the FDACompletion of this financing ...

Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects to Report One-Year Cohort 1 Data and Early Cohort 2 Data from RIDGE™-1 Study of TN-401 for PKP2-Associated ARVC in First Half of 2026 Plans to Pursue Alignment on Regulatory Pathways for Lead Gene Therapy Programs in 2026 Raised $60 Million in 4Q25 to Support Runway Through mid-2027 SOUTH SAN FRANCISCO, Calif., Jan ...

Geneva, Switzerland, Jan. 09, 2026 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, and a subsidiary of WISeKey International Holding AG (Nasdaq: WKEY; SIX: WIHN) (“WISeKey”), today announced that it has reached a final, binding agreement with Kaynes SemiCon to establish SEALKAYNESQ Ltd, a Joint Venture (“JV”) in India. The JV is being formed with the obje ...

NANO Nuclear Energy Inc. NANO Nuclear Energy Announces Dismissal of Federal Securities Lawsuit. Dismissal of Federal Securities Class Action Lawsuit Follows Dismissal of Related Shareholder Derivative Lawsuit. Dismissal of Federal Securities Class Action Lawsuit Follows Dismissal of Related Shareholder Derivative Lawsuit New York, NY, Jan. 09, 2026 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor (MMR) and tech ...